Table I.
Study | Patients(PRP/control) | Control | Inclusion criteria | Follow-up duration | Outcome measurement | ||
---|---|---|---|---|---|---|---|
Tear time, months | Size | Shoulder function | Pain | ||||
Rha et al. 2013 (17) | 16/14 | Placebo (dry needles) | > 6 | < 1.0 cm | 6 months | SPADI | Pain in SPADI |
Ilhanli et al. 2015 (26) | 30/32 | Physical therapy | Not mentioned | Not mentioned | 12 months | DASH score | VAS score |
von Wehren et al. 2016 (22) | 25/25 | Corticosteroids | > 2 | Not mentioned | 6 months | SST score, CS, ASES score | VAS score (specific data were not given) |
Shams et al. 2016 (21) | 20/20 | Corticosteroids | > 3 | Not mentioned | 6 months | SST score, CS, ASES score | VAS score (specific data were not given) |
Cai et al. 2019 (16) | 45/47 | Placebo (saline) | < 6 | < 1.0 cm | 1 year | CS, ASES score | VAS score |
Schwitzguebel et al. 2019 (18) | 41/39 | Placebo (saline) | > 6 | Not mentioned | > 12 months | ASES score | VAS score |
Ibrahim et al. 2019 (25) | 15/15 | Corticosteroids | Not mentioned | Not mentioned | 7 months | SDQ score | VAS score |
Cory et al. 2020 (19) | 52/47 | Corticosteroids | > 3 | Not mentioned | 1 year | ASES score, WORC score | VAS score |
Sari et al. 2020 (20) | 30/30 | Corticosteroids | > 3 | Grade 1 | 24 weeks | ASES score, WORC score | VAS score |
Dadgostar et al. 2021 (23) | 30/28 | Corticosteroids | > 3 | Not mentioned | 3 months | WORC score, DASH score | VAS score |
Thepsoparn et al. 2021 (24) | 15/16 | Corticosteroids | > 3 | Not mentioned | 6 months | OSS | VAS score |
SPADI: Shoulder Pain and Disability Index; SST: simple shoulder test; CS: Constant (Murley) score; ASES: American Shoulder and Elbow Surgeons Standardized Shoulder Assessment Form; WORC: Western Ontario Rotator Cuff; SDQ: Strength and Difficulties Questionnaire; DASH: Disabilities of the Arm, Shoulder and Hand; OSS: Oxford Shoulder Score; VAS: visual analogue scale.